Annovis Bio, Inc.(ANVS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ANVS Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Annovis Bio, Inc. (ANVS), a Healthcare sector company. ANVS is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of ANVS by reported 13-F value include Empery Asset Management, MARSHALL WACE, LLP, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ANVS trades on the NYSE exchange and files with the SEC under CIK 1477845. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANVS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Annovis Bio, Inc. directly from SEC EDGAR.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-14.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-17.3% YoYOperating Income
-11.2% YoYEPS (Diluted)
+39.4% YoYTotal Assets
+51.4% YoYOp. Cash Flow
-17.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $-28.9M -17.3% | $-24.6M +56.2% | $-56.2M -121.9% | $-25.3M -74.8% | $-14.5M -165.2% | $-5.5M |
| Operating Income | $-29.7M -11.2% | $-26.7M +40.7% | $-45.0M -76.5% | $-25.5M -75.5% | $-14.5M -118.9% | $-6.6M |
| EPS (Diluted) | $-1.40 +39.4% | $-2.31 +62.9% | $-6.23 -101.0% | $-3.10 -63.2% | $-1.90 -118.4% | $-0.87 |
| Total Assets | $21.1M +51.4% | $13.9M +36.4% | $10.2M -71.7% | $36.0M -21.7% | $46.0M +466.6% | $8.1M |
| Operating Cash Flow | $-25.6M -17.0% | $-21.9M +45.2% | $-40.0M -130.9% | $-17.3M -89.6% | $-9.1M -130.0% | $-4.0M |
Get alerted when ANVS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Annovis Bio, Inc. including:
Top Institutional Holders of ANVS
Empery Asset Management, LP
$4.5M2,401,476 shMARSHALL WACE, LLP
$3.4M1,842,339 shVANGUARD CAPITAL MANAGEMENT LLC
$3.1M1,647,322 shTUDOR INVESTMENT CORP ET AL
$2.5M1,357,134 shRENAISSANCE TECHNOLOGIES LLC
$1.9M1,002,200 shTWO SIGMA INVESTMENTS, LP
$1.1M579,571 shCaption Management, LLC
$883.3K474,900 shGROUP ONE TRADING, L.P.
$789.4K424,400 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$531.8K285,900 shGEODE CAPITAL MANAGEMENT, LLC
$528.1K283,817 sh
| Fund | Value | Shares |
|---|---|---|
| Empery Asset Management, LP | $4.5M | 2,401,476 |
| MARSHALL WACE, LLP | $3.4M | 1,842,339 |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.1M | 1,647,322 |
| TUDOR INVESTMENT CORP ET AL | $2.5M | 1,357,134 |
| RENAISSANCE TECHNOLOGIES LLC | $1.9M | 1,002,200 |
| TWO SIGMA INVESTMENTS, LP | $1.1M | 579,571 |
| Caption Management, LLC | $883.3K | 474,900 |
| GROUP ONE TRADING, L.P. | $789.4K | 424,400 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $531.8K | 285,900 |
| GEODE CAPITAL MANAGEMENT, LLC | $528.1K | 283,817 |
More Healthcare Companies
View all Healthcare →Put ANVS on your watchlist
Track score changes the day Annovis Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ANVS a good stock to buy?
13F Pro's AI-powered analysis of Annovis Bio, Inc. (ANVS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANVS are available on the ANVS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ANVS is classified as a small company.
Which hedge funds own ANVS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANVS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Annovis Bio, Inc.'s investment landscape.